Publications by authors named "Eduardo Saul"
Comprehensive information on clinical features and long-term outcomes of primary conjunctival extranodal marginal zone lymphoma (PCEMZL) is scarce. We present a large single-institution retrospective study of 72 patients. The median age was 64 years, and 63.
View Article and Find Full Text PDFArticle Synopsis
- Colon extranodal marginal zone lymphoma (EMZL) is not well-studied, so researchers conducted a review of cases from their institution and the SEER database to gather more information.
- Out of the eight patients at the institution, most had stage-I disease, and initial treatments included active surveillance, polypectomy, and surgical resection, with five of six treated patients achieving complete remission.
- The SEER database showed a 10-year overall survival rate of 73.9% among 361 patients with stage-I colon EMZL, highlighting the disease's indolent nature and suggesting non-aggressive treatment strategies could be effective.
Article Synopsis
- Breast extranodal marginal zone lymphoma (EMZL) is a rare type of cancer, with this study being the largest retrospective analysis of 13 patients focusing on its characteristics and treatment results.
- Most patients were in early stages (I-II), but about 30% had advanced stage IV disease due to hidden issues like bone marrow involvement; additionally, two-thirds of cases were not detected on PET/CT scans.
- The results showed promising outcomes with a 68.7% rate of progression-free survival and 80.2% overall survival over a median follow-up of 3.1 years, indicating that radiation therapy can effectively manage localized breast EMZL.
Background: Studies suggest that surgical breast augmentation with implants is a risk factor for breast desmoid tumors. The statistical strength of this correlation is unknown, as evidence is limited to anecdotal reports.
Methods: Patients with breast desmoid tumors and a history of breast implants seen at a single center between 2000 and 2021 were identified via radiology, breast, and sarcoma databases.
Hemophagocytic lymphohistiocytosis (HLH) is a systemic inflammation disorder secondary to immune dysregulation. Patients may present with fevers, splenomegaly, bone marrow failure and hemophagocytosis, among other clinical and laboratory findings. Lymphoma-associated HLH (LA-HLH) is a puzzling diagnosis given both conditions overlapping presentation.
View Article and Find Full Text PDFPurpose: Inferior outcomes of Black patients with lung cancer compared with other racial groups are often linked to socioeconomic factors. It is crucial to determine whether a varying prevalence of targetable mutations limits treatments and contributes to disparities.
Materials And Methods: We conducted a meta-analysis on the prevalence of lung cancer , , , and mutations in Black patients compared with White, Hispanic, and Asian patients.
We present long-term combined results of two clinical trials implementing R-MACLO-IVAM induction followed by thalidomide or rituximab maintenance in 44 patients with untreated mantle cell lymphoma (MCL). The first 22 patients (UM-MCL1 ClinicalTrials.gov identifier NCT00450801) received maintenance with thalidomide (200 mg daily until relapse/intolerable toxicity) and a subsequent cohort of 22 patients (UM-MCL2 ClinicalTrials.
View Article and Find Full Text PDF